
CATX Stock Forecast & Price Target
CATX Analyst Ratings
Bulls say
Perspective Therapeutics is a company with strong potential for future growth, as evidenced by its cutting-edge technology that utilizes alpha-emitting isotope Lead-212 to specifically target and destroy cancer cells. Their clinical data for their product candidates have shown consistent and compelling efficacy and safety. With upcoming data catalysts and a healthy financial position, the company is well-positioned for future success and our analysis suggests a strong buy rating with a potential price target of $14 per share.
Bears say
Perspective Therapeutics is currently trading at a discount to its sum-of-parts valuation due to uncertainty around its lead programs and lack of near-term positive catalysts. Additionally, the company's reliance on partnerships for further development and commercialization of its products may limit potential revenue generation. Without significant positive developments or partnerships, the stock may struggle to gain traction and reach its full potential in the market.
This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
CATX Analyst Forecast & Price Prediction
Start investing in CATX
Order type
Buy in
Order amount
Est. shares
0 shares